Pre-Treatment and Post-Treatment Demodex Densities in Patients under Immunosuppressive Treatments

Hacer Keles, Esra Pancar Yuksel, Fatma Aydin, Nilgun Senturk, Hacer Keles, Esra Pancar Yuksel, Fatma Aydin, Nilgun Senturk

Abstract

Background and Objectives: Demodex species are common obligatory parasites and normally present in low number in human beings. Immunosuppression was suggested to be associated with increased density of Demodex mites. Systemic glucocorticoids, cyclosporine, methotrexate, and azathioprine are commonly used immunosuppressive agents. We aim to determine the pre- and post-treatment Demodex densities in patients receiving immunosuppressive therapy and compare with those of healthy subjects. Materials and Methods: Demodex density was investigated at the beginning, first, and third months of the immunosuppressive therapy in 45 patients who received methotrexate, cyclosporine, systemic steroid, or azathioprine treatments and in 45 healthy subjects at the same time as the patients. Five standardized skin surface biopsies were taken from cheeks, forehead, nose, and chin of the patients and control group. The presence of five or more parasites in 1 cm2 area was considered as positive. Results: Demodex test was negative at the beginning of the treatment in all patients. Demodex test was positive in one patient in the first and third months of treatment and in three patients only in the third month of treatment. In the control group, Demodex test was determined as positive in just one healthy individual at the beginning, first and third months of the study. When the patient and control groups were evaluated in terms of Demodex number, there was a statistically significant difference in Demodex density in patients treated with immunosuppressive treatment in the first and third months when compared with the control group (p < 0.05). Conclusion: Immunosuppressive treatment might increase the number of Demodex mites and demodicidosis should be kept in mind in patients on immunosuppressive treatment.

Keywords: azathioprine; corticosteroids; cyclosporine; demodex; immunosuppressive treatment; methotrexate.

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Elston C.A., Elston D.M. Demodex mites. Clin Dermatol. 2014;32:739–743. doi: 10.1016/j.clindermatol.2014.02.012.
    1. Baima B., Sticherling M. Demodicidosis revisited. Acta Derm. Venereol. 2002;82:3–6. doi: 10.1080/000155502753600795.
    1. Rufli T., Mumcuoglu Y. The hair follicle mites Demodex folliculorum and Demodex brevis: biology and medical importance. A review. Dermatologica. 1981;162:1–11. doi: 10.1159/000250228.
    1. Akilov O.E., Mumcuoglu K.Y. Immune response in demodicosis. J. Eur. Acad. Dermatol. Venereol. 2004;18:440–444. doi: 10.1111/j.1468-3083.2004.00964.x.
    1. Hsu C.K., Hsu M.M., Lee J.Y. Demodicosis: a clinicopathological study. J. Am. Acad. Dermatol. 2009;60:453–462. doi: 10.1016/j.jaad.2008.10.058.
    1. Seyhan M.E., Karincaoğlu Y., Bayram N., Aycan O., Kuku I. Density of Demodex folliculorum in haematological malignancies. J. Int. Med. Res. 2004;32:411–415. doi: 10.1177/147323000403200410.
    1. Chang Y.S., Huang Y.C. Role of Demodex mite infestation in rosacea: A systematic Review and meta-analysis. J. Am. Acad. Dermatol. 2017;77:441–447.e6. doi: 10.1016/j.jaad.2017.03.040.
    1. Lacey N., Ní Raghallaigh S., Powell F.C. Demodex mites--commensals, parasites or Mutualistic organisms? Dermatology. 2011;222:128–130. doi: 10.1159/000323009.
    1. Fujiwara S., Okubo Y., Irisawa R., Tsuboi R. Rosaceiform dermatitis associated with topical tacrolimus treatment. J. Am. Acad. Dermatol. 2010;62:1050–1052. doi: 10.1016/j.jaad.2009.01.029.
    1. Aydingöz I.E., Dervent B., Güney O. Demodex folliculorum in pregnancy. Int. J. Dermatol. 2000;39:743–745. doi: 10.1046/j.1365-4362.2000.00013.x.
    1. Jansen T., Kastner U., Kreuter A., Altmeyer P. Rosacea-like demodicidosis associated with acquired immunodeficiency syndrome. Br. J. Dermatol. 2001;144:139–142. doi: 10.1046/j.1365-2133.2001.03794.x.
    1. Sahn E.E., Sheridan D.M. Demodicidosis in a child with leukemia. J. Am. Acad. Dermatol. 1992;27:799–801. doi: 10.1016/0190-9622(92)70250-J.
    1. Ivy S.P., Mackall C.L., Gore L., Gress R.E., Hartley A.H. Demodicidosis in childhood acute lymphoblastic leukemia; an opportunistic infection occurring with immunosuppression. J. Pediatr. 1995;127:751–754. doi: 10.1016/S0022-3476(95)70168-0.
    1. Castanet J., Monpoux F., Mariani R., Ortonne J.P., Lacour J.P. Demodicidosis in an immunodeficient child. Pediatr. Dermatol. 1997;14:219–220. doi: 10.1111/j.1525-1470.1997.tb00242.x.
    1. Morrás P.G., Santos S.P., Imedio I.L., Echeverria M.L., Hermosa J.M. Rosacea-like demodicidosis in an immunocompromised child. Pediatr. Dermatol. 2003;20:28–30. doi: 10.1046/j.1525-1470.2003.03006.x.
    1. Dominey A., Rosen T., Tschen J. Papulonodular demodicidosis associated with acquired immunodeficiency syndrome. J. Am. Acad. Dermatol. 1989;20:197–201. doi: 10.1016/S0190-9622(89)70021-9.
    1. Redondo Mateo J., Soto Guzmán O., Fernández Rubio E., Dominguez Franjo F. Demodex-attributed rosacea-like lesions in AIDS. Acta Derm. Venereol. 1993;73:437. doi: 10.2340/0001555573437.
    1. Sarro R.A., Hong J.J., Elgart M.L. An unusual demodicidosis manifestation in a patient with AIDS. J. Am. Acad. Dermatol. 1998;38:120–121. doi: 10.1016/S0190-9622(98)70554-7.
    1. Pesanti E.L. Immunologic defects and vaccination in patients with chronic renal failure. Infect. Dis. Clin. North. Am. 2001;15:813–832. doi: 10.1016/S0891-5520(05)70174-4.
    1. Karincaoglu Y., Esrefoglu Seyhan M., Bayram N., Aycan O., Taskapan H. Incidence of Demodex folliculorum in patients with end stage chronic renal failure. Ren. Fail. 2005;27:495–499. doi: 10.1080/08860220500198037.
    1. Yagdiran Düzgün O., Aytekin S. Comparison of Demodex folliculorum density in haemodialysis patients with a control group. J. Eur. Acad. Dermatol. Venereol. 2007;21:480–483. doi: 10.1111/j.1468-3083.2007.01926.x.
    1. Antille C., Saurat J.H., Lübbe J. Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch. Dermatol. 2004;140:457–460. doi: 10.1001/archderm.140.4.457.
    1. Lübbe J., Stucky L., Saurat J.H. Rosaceiform dermatitis with follicular Demodex after treatment of facial atopic dermatitis with 1% pimecrolimus cream. Dermatology. 2003;207:204–205. doi: 10.1159/000071800.
    1. Kaya S., Selimoglu M.A., Kaya O.A., Ozgen U. Prevalence of Demodex folliculorum and Demodex brevis in childhood malnutrition and malignancy. Pediatr. Int. 2013;55:85–89. doi: 10.1111/j.1442-200X.2012.03740.x.
    1. Inci M., Kaya O.A., Inci M., Yula E., Gökçe H., Rifaioğlu M.M., Demirtaş O., Yengil E. Investigating Demodex folliculorum in patients with urological cancer. Turkiye. Parazitol. Derg. 2012;36:208–210. doi: 10.5152/tpd.2012.50.
    1. Szkaradkiewicz A., Chudzicka-Strugała I., Karpiński T.M., Goślińska-Pawłowska O., Tułecka T., Chudzicki W., Szkaradkiewicz A.K., Zaba R. Bacillus oleronius and Demodex mite infestation in patients with chronic blepharitis. Clin. Microbiol. Infect. 2012;18:1020–1025. doi: 10.1111/j.1469-0691.2011.03704.x.
    1. Biernat M.M., Rusiecka-Ziółkowska J., Piątkowska E., Helemejko I., Biernat P., Gościniak G. Occurrence of Demodex species in patients with blepharitis and in healthy individuals: a 10-year observational study. Jpn. J. Ophthalmol. 2018;62:628–633. doi: 10.1007/s10384-018-0624-3.
    1. Navel V., Mulliez A., Benoist d’Azy C., Baker J.S., Malecaze J., Chiambaretta F., Dutheil F. Efficacy of treatments for Demodex blepharitis: A systematic review and meta-analysis. Ocul. Surf. 2019;17:655–669. doi: 10.1016/j.jtos.2019.06.004.
    1. Schadt C.R., Jackson S.M. In: Dermatology. Bolognia J.L., Schaffer J.V., Cerroni L., editors. Volume 2. Elsevier Saunders; Philadelphia, PA, USA: 2018. pp. 2186–2199. Chapter 125.
    1. Maiberger M.P., Nunley J.R., Wolverton S.E. In: Dermatology. Bolognia J.L., Schaffer J.V., Cerroni L., editors. Volume 2. Elsevier Saunders; Philadelphia, PA, USA: 2018. pp. 2278–2295. Chapter 130.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit